期刊文献+

32例子宫平滑肌肉瘤的诊治及预后因素 被引量:1

DIAGNOSIS,THERAPY AND PROGNOSTIC FACTORS OF 32 UTERINE LEIOMYOSARCOMAS
下载PDF
导出
摘要 目的 研究32 例子宫平滑肌肉瘤的诊治及预后因素。 方法 1962 年7 月~1994 年10 月,收治32例子宫平滑肌肉瘤,其中Ⅰ期11 例,Ⅱ期4 例,Ⅲ期14 例,Ⅳ期3 例,32 例均行手术治疗,术后补充化疗16 例,补充放疗8 例,补充化疗加放疗7 例。 结果 本组病例总的二年及五年生存率分别为552% 及365 % 。Ⅰ~Ⅱ期的二年及五年生存率为733% 及643 % ,Ⅲ~Ⅳ期的二年及五年生存率为357 % 及0 % 。 结论 子宫平滑肌肉瘤预后和临床分期、治疗方法、子宫大小、绝经因素等有明显关系,术后辅以化疗和放疗有可能提高生存率。 To investigate the clinical features of 32 uterine leiomyosarcomas.METHODS 32 cases of uterine leiomyosarcoma were studied.Among them,11 cases were in stage Ⅰ,4 stage Ⅱ,14 stage Ⅲ and 3 stage Ⅳ.32 cases were treated by surgery alone,16 cases by surgery plus chemotherapy,8 cases by surgery plus radiation,7 cases by surgery combined with chemotherapy and radiation therapy.RESULTS In the series, the overall 2 and 5 year survival rates were 55.2% and 36% respectively.The 2 and 5 year survival rates for the 15 cases with stage Ⅰ-stageⅡ were 73.3% and 64.3%, for 17 cases with stage Ⅲ-stage Ⅳ were 35.7% and 0%.CONCLUSIONS The clinical stage, treatment methods,uterine size and menopausal status generally are significantly prognostic factors.Postsurgical adjuvant radiotherapy and chemotherapy significantly improve survival.
出处 《中国癌症杂志》 CAS CSCD 1999年第3期193-194,199,共3页 China Oncology
关键词 子宫平滑肌肉瘤 诊断 治疗 预后 子宫肿瘤 Leiomyosarcoma Diagnosis Therapy Prognosis
  • 相关文献

同被引文献23

  • 1Wu TI, Chang TC, Hsueh S, et al. Prognostic factors and impact of adjuvant chemotherapy for uterine leiomyosarcoma [ J ]. Gynecol Oncol, 2006, 100( 1 ) : 166-172.
  • 2Mayerhofer K, Obermair A, Windbichler G, et al. Leiomyosarcoma of the uterus: a clinicopathologic multicenter study of 71 cases[J]. Gynecol Oncol, 1999, 74(2): 196-201.
  • 3Livi L, Paiar F, Shah N, et al. Uterine sarcoma: twenty-seven years of experience[ J]. Int J Radiat Oncol Biol Phys, 2003, 57 (5) : 1366-1373.
  • 4Bodner K, Bodner-Adler B, Kimberger O, et al. Estrogen and progesterone receptor expression in patients with uterine smooth muscle tumors[J]. Fertil Steril, 2004, 81(4) : 1062-1066.
  • 5Dinh TA, Oliva EA, Fuller AF Jr, et al. The treatment of uterine leiomyosareoma: results from a 10-year experience (1990- 1999) at the Massachusetts General Hospital[ J]. Gynecol Oncol, 2004, 92(2) : 648-652.
  • 6Kokawa K, Nishiyama K, Ikeuchi M, et al. Clinical outcomes of uterine sarcomas: results from 14 years worth of experience in the Kinki district in Japan (1990-2003) [ J]. Int J Gynecol Cancer, 2006, 16(3): 1358-1363.
  • 7Giuntoli RL 2nd, Metzinger DS, DiMarco CS, et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy[J]. Gynecol Oncol, 2003, 89(3): 460-469.
  • 8Anderson SE, Nonaka D, Chuai S, et al. p53, epidermal growth factor, and platelet-derived growth factor in uterine leiomyosarcoma and leiomyomas[ J]. Int J Gynecol Cancer, 2006, 16(2) : 849-853.
  • 9Bodner K, Bodner-Adler B, Kimberger O, et al. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma[J]. J Soc Gynecol Investig, 2004, 11 (3): 187-191.
  • 10Leiser AL, Anderson SE, Nonaka D, et al. Apoptotic and cell cycle regulatory markers in uterine leiomyosarcoma[ J]. Gynecol Oncol, 2006, 101 ( 1 ) : 86-91.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部